Patents Examined by Eric Olson
  • Patent number: 10960078
    Abstract: The invention provides novel amphiphilic drug-drug conjugates useful as cancer therapeutics, and compositions and methods thereof.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: March 30, 2021
    Assignee: Shanghai Jiao Tong University
    Inventors: Deyue Yan, Ping Huang, Xinyuan Zhu, Wei Huang, Yongfeng Zhou
  • Patent number: 10953037
    Abstract: A compound includes a group derived from chondroitin sulfate, a group derived from a steroid, and a spacer. The group derived from the chondroitin sulfate and the group derived from the steroid are covalently bonded together via the spacer, and a spacer forming molecule of the spacer is ?-alanine or isoleucine. A covalent bond between the group derived from the steroid and the spacer is an ester bond, and a covalent bond between the group derived from the chondroitin sulfate and the spacer is an amide bond. The steroid is at least one selected from the group consisting of prednisolone, betamethasone, triamcinolone, triamcinolone acetonide, budesonide and fluticasone.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: March 23, 2021
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Muneto Narita, Takahiro Hatanaka, Yuko Yoshida
  • Patent number: 10954314
    Abstract: A method of disintegrating pulp for use in cellulose acetate production includes: a primary disintegration step of disintegrating a pulp sheet into pulp pieces having an average area of not more than 45 cm2; and a secondary disintegration step of disintegrating the pulp pieces with an impact shock exerted by a jet mill (20). The jet mill (20) includes: a cylindrical casing (21) provided with an inlet (21d) and an outlet (21e); and a rotor (25) including a plurality of blades (25a) provided on its outer peripheral portion, the plurality of blades (25a) facing an inner peripheral surface of the casing (21).
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: March 23, 2021
    Assignee: DAICEL CORPORATION
    Inventors: Mitsuteru Hosaka, Toshinori Okano, Yuji Ida
  • Patent number: 10953098
    Abstract: The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: March 23, 2021
    Assignees: The Regents of the University of California, Alchemical Research Holdings, LLC
    Inventors: Jose Manuel Mejia Oneto, Ziyad F. Al-Rashid
  • Patent number: 10946032
    Abstract: The invention relates to a mixture of human milk oligosaccharides that consists essentially of: a) a component A which is 3-FL or DFL, a component B which is LNT, LNnT, LNFP-I or 2?-FL, a component C, which is LNFP-II when component B is LNT, or LNFP-III when component B is LNnT, or LNDFH-I when component B is LNFP-I, or DFL when component B is 2?-FL, and a component D, which is lactose when component A is 3-FL, or 2?-FL when component A is DFL, with the proviso that if component B is 2?-FL, then component A is 3-FL; or consists essentially of: b) 3-FL, a component E which is LNT, LNnT or LNFP-I, and a component F, which is LNFP-II when component E is LNT, or LNFP-III when component E is LNnT, or LNDFH-I when component E is LNFP-I, and to processes for producing them and their uses.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: March 16, 2021
    Assignee: GLYCOM A/S
    Inventors: Elise Champion, Bruce McConnell, Gyula Dekany
  • Patent number: 10941218
    Abstract: Provided is a carboxymethyl cellulose or a salt thereof, in which when the carboxymethyl cellulose or the salt thereof is used as a binding agent for an electrode of a nonaqueous electrolyte secondary battery, defects, such as pinholes, on a surface of the electrode are reduced and a battery including the electrode has a good capacity retention. A method for producing a carboxymethyl cellulose or a salt thereof includes an alkali cellulose formation step (step 1) of allowing cellulose and an alkali to react with each other in the presence of a mixed solvent containing water and an organic solvent, an etherification step (step 2) of allowing the resulting alkali cellulose and an etherifying agent to react with each other, a purification step (step 3) of washing and drying the resulting reaction mixture, and a pulverization step (step 4) of pulverizing the resulting purified product.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: March 9, 2021
    Assignee: DAI-ICHI KOGYO SEIYAKU CO., LTD.
    Inventors: Ryo Kakubari, Atsushi Sanuki
  • Patent number: 10941173
    Abstract: The invention provides derivatives of rhamnolipids, formulations comprising these, and the use thereof.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: March 9, 2021
    Assignee: Evonik Operations GmbH
    Inventors: Xin Lu, Sandra Nattland, Monica Desiree van Logchem, Hans Henning Wenk, Fabien Cabirol, Verena Dahl, Ralph Scheuermann, Kathrin Daniela Brandt, Jochen Kleinen
  • Patent number: 10940198
    Abstract: The present invention relates to a herpes zoster vaccine composition, which comprises glycoprotein E of Varicella zoster virus, a glucopyranosyl lipid adjuvant, and a metabolic oil, and selectively increases a cell-mediated immune reaction without having disadvantages of attenuated live vaccines, thereby exhibit high safety and a high preventive effect against herpes zoster.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: March 9, 2021
    Assignees: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, INFECTIOUS DISEASE RESEARCH INSTITUTE
    Inventors: Hyo Jung Nam, Eun Mi Kim, Duck Hyang Shin, Steven G. Reed, Kang Il Yoo, Sung Jun Hong
  • Patent number: 10925891
    Abstract: The present invention relates to determining the carrier status of Annexin A5 M2 haplotype of parents (both male and female) prior to and/or after pregnancy to minimize the risk of pregnancy complications, including, but not limited to, recurrent pregnancy loss (RPL), infertility, miscarriage, in vitro fertilization (IVF) failure, IUI failure, implantation failure, foetal growth restriction (FGR), small for gestational age (SGA) newborn, intra-uterine foetal death (IUFD), gestational hypertension (GH), pre-eclampsia (PE) and/or venous thromboembolism (VTE). Once M2 carrier status is determined, methods of intervention, including administration of low molecular weight heparin (LMWH) and/or other anti-coagulants can be administered either prior to and/or after pregnancy. Methods of detecting the carrier status as well as method of diagnosing and or predicting prognosis based on the M2 carrier status of a patient and/or couple is also contemplated.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: February 23, 2021
    Assignee: IHG Pharmaco Ltd.
    Inventor: Deborah Jane Baker
  • Patent number: 10918659
    Abstract: The present invention describes a method for preparing a polymannan extract from freeze-dried aloe powder. The polymannan extract of the present invention is further used to formulate a sterile injectable formulation for the treatment of one or more cancers, leukemias and lymphomas, prostate cancer, breast cancer, and colon cancer, immune diseases, particularly immune related neoplasms, acquired immune deficiency syndrome, and hepatitis C.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: February 16, 2021
    Assignee: Bespoke Bioscience, LLC
    Inventor: Ivan E. Danhof
  • Patent number: 10918709
    Abstract: The present invention relates to an immune modulator having a novel structure, and an immunologic adjuvant composition containing the same and, more specifically, to an modulator, which is a lipopolysaccharide (LPS) analog having reduced toxicity, and a use thereof. The immune modulator of the present invention exhibits immune enhancement effects by having excellent innate immunity and ability to induce an adaptive immune response to a specific pathogen, and is very safe by having low toxicity. In addition, a vaccine containing the immune modulator of the present invention contains both an immune modulator and an alum, thereby improving immune enhancement effects compared with when using only the immune modulator.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: February 16, 2021
    Assignee: EYEGENE INC.
    Inventors: Yang Je Cho, Kwangsung Kim, Na Gyong Lee, Shin Ae Park
  • Patent number: 10913763
    Abstract: An object of the invention is to provide a method of uniformly and efficiently producing a saccharide having a sulfate group and/or a phosphate group in the molecule, or a compound containing the saccharide. [Solution] The present invention provides a method of producing a saccharide having a sulfate group and/or a phosphate group. The method comprises (a) a step of preparing a “first saccharide having a non-protected sulfate group and/or a non-protected phosphate group” and a “second saccharide having a non-protected sulfate group and/or a non-protected phosphate group” and (b) a step of condensing the first saccharide and the second saccharide prepared in the step (a) with each other.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: February 9, 2021
    Assignee: GLYTECH, INC.
    Inventors: Yasuhiro Kajihara, Akihiro Manbo, Takefumi Murase
  • Patent number: 10899894
    Abstract: A method of preparing a hydrogel product including crosslinked glycosaminoglycan molecules, said method including: i) providing a glycosaminoglycan crosslinked by amide bonds, wherein the crosslinked glycosaminoglycans include residual amine groups; and ii) acylating residual amine groups of the crosslinked glycosaminoglycans provided in i) to form acylated crosslinked glycosaminoglycans.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: January 26, 2021
    Assignee: GALDERMA S.A
    Inventors: Johan Olsson, Craig Steven Harris
  • Patent number: 10899913
    Abstract: A method for producing a crosslinked gel. The method comprises steps of: (a) combining (i) water, (ii) alginic acid, alginates, or mixtures thereof, (iii) carboxymethylcellulose, (iv) a salt of calcium, magnesium or zinc, (v) a nonionic surfactant and (vi) fragrance to form a gel having a surface; and (b) contacting with the surface of said gel an additional aqueous solution of a salt of calcium, magnesium or zinc.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: January 26, 2021
    Assignees: Rohm and Haas Company, Union Carbide Corporation
    Inventors: Andrea C. Keenan, Emmett M. Partain, III, Theodore Tysak, Jennifer J. Todd
  • Patent number: 10889610
    Abstract: The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: July 9, 2017
    Date of Patent: January 12, 2021
    Assignee: GALECTO BIOTECH AB
    Inventors: Fredrik Zetterberg, Ulf Nilsson, Hakon Leffler
  • Patent number: 10889576
    Abstract: The invention relates to a compound of Formula I and methods of treating CFTR (cystic fibrosis transmembrane conductance regulator) mediated diseases, in particular cystic fibrosis, comprising the step of administering a therapeutically effective amount of a compound of Formula I to a patient in need thereof:
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: January 12, 2021
    Assignee: Flatley Discovery Lab, LLC
    Inventor: Bridget M. Cole
  • Patent number: 10881674
    Abstract: The invention relates to a method for stabilising or reducing insulin resistance in patients having an obesity-related, metabolic disorder, the method comprising administering to the patient an effective amount of one or more human milk oligosaccharides (HMOs).
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: January 5, 2021
    Assignee: GLYCOM A/S
    Inventors: Bruce McConnell, Louise Kristine Vigsnæs, Emma Elison
  • Patent number: 10874682
    Abstract: The present invention relates to a composition comprising a pharmaceutically acceptable carrier, at least one compound of the avermectin family, and at least one non-steroidal anti-inflammatory compound. The present invention further provides such composition for use in the treatment and/or the prevention of rosacea.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: December 29, 2020
    Assignee: NESTLÉ SKIN HEALTH SA
    Inventors: Jean Jacovella, Olivier Roye, André Jomard
  • Patent number: 10874684
    Abstract: Compositions and method are therefore disclosed for treating ARDS. In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated precursors selected from the group consisting of CDP-choline, CDP-ethanolamine, and CDP-diacylglycerol (CDP-DAG) in a pharmaceutically acceptable carrier for use in treating ARDS.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: December 29, 2020
    Assignee: Ohio State Innovation Foundation
    Inventor: Ian Christopher Davis
  • Patent number: 10874733
    Abstract: The present invention relates to an immunity enhancing composition including an immune response modulator having a novel structure and, more specifically, to an immunity enhancing composition and a use of the same, wherein the immunity enhancing composition includes a lipopolysaccharide (LPS) analogue with reduced toxicity, and a cationic liposome. The present invention overcomes the physicochemical instability of a liposome, is advantageous in terms of production, transportation, and storage, and improves stability, thus being beneficial as an immune delivery system. In addition, the present invention includes an immune response modulator, and a cationic liposome, and thus exhibits an enhanced immunity-improving effect compared to the case in which an immune response modulator is used alone.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: December 29, 2020
    Assignee: EYEGENE INC.
    Inventors: Yang Je Cho, Kwangsung Kim, Na Gyong Lee, Shin Ae Park